Cardlytics CFO Alexis DeSieno sells shares worth over $59,000 By Investing.com

Cardlytics, Inc. (NASDAQ:) Chief Financial Officer, Alexis DeSieno, has recently sold a portion of her holdings in the company. On July 2, 2024, DeSieno sold 7,451 shares of Cardlytics common stock at an average price of $7.953 per share, totaling over $59,257 in value. The transactions were carried out in multiple sales with prices ranging from $7.85 to $8.12.

This sale was primarily executed to satisfy tax withholding obligations associated with the vesting of restricted stock units (RSUs) on July 1, 2024. It is important to note that the shares were not sold for any other purpose, as indicated in the footnotes of the SEC filing. Following this transaction, DeSieno still owns 6,898 shares of common stock directly.

In addition to the sale, on July 1, DeSieno received 14,349 RSUs, each representing a contingent right to receive one share of Cardlytics common stock. These RSUs are part of an award that is set to vest in eight equal installments over a two-year period, provided DeSieno remains employed with the company through each vesting date.

Investors often monitor insider transactions as they may provide insights into the executives’ perspectives on the company’s current valuation and future prospects. The recent activities by the CFO of Cardlytics, Inc. have been duly reported in compliance with SEC regulations.

In other recent news, Cardlytics has reported a strong start to the year, with first-quarter earnings revealing a 12% increase in billings and a significant rise in adjusted contribution, marking the first time the company has reported a positive adjusted EBITDA for a first quarter. The company also raised $50 million in cash and made strategic moves to improve its capital structure. Despite a negative operating cash flow, Cardlytics expects it to turn positive in the second half of the year.

BofA Securities resumed coverage on Cardlytics, issuing a Neutral rating and setting a price target of $11.00. The firm acknowledged Cardlytics’ strong relationships with financial institutions but pointed out potential challenges in attracting more advertising dollars and product innovation. Northland initiated coverage on Cardlytics, assigning an Outperform rating and setting a price target of $14.00, reflecting confidence in Cardlytics’ potential in the digital advertising sector.

The company’s revenue growth was noted in both the U.S. and U.K., with the U.K. experiencing a 56% increase. For the upcoming second quarter, Cardlytics forecasts billings between $115 million and $126 million, and revenue estimates between $73 million and $81 million. In addition to financial growth, Cardlytics is investing in sales and technology, including the development of a self-serve platform for advertisers and the expansion of the Bridg retail media network. These are the recent developments in the company’s journey.

InvestingPro Insights

As Cardlytics, Inc. (NASDAQ:CDLX) navigates through its financial journey, several key metrics and insights from InvestingPro provide a clearer picture of the company’s current status. With a market capitalization of approximately $383.43 million, Cardlytics’ scale in the market is modest, reflecting the potential room for growth or consolidation within its industry.

One of the notable InvestingPro Tips for CDLX is that analysts do not anticipate the company will be profitable this year, which aligns with the negative P/E ratio of -1.8. This metric underscores the challenges Cardlytics faces in terms of earnings, as it has not been profitable over the last twelve months. Additionally, the company’s stock price has experienced significant volatility, with a 42.64% decline over the last three months, indicating a period of investor uncertainty.

Despite these challenges, Cardlytics’ liquid assets exceed its short-term obligations, suggesting a degree of financial flexibility. This is an important consideration for investors who are assessing the company’s ability to manage its immediate financial commitments.

For those interested in delving deeper into the company’s financial health and future prospects, InvestingPro offers additional insights and tips. There are currently 6 more InvestingPro Tips available for Cardlytics, which can be accessed by visiting https://www.investing.com/pro/CDLX. To enrich your analysis, use the coupon code PRONEWS24 to get up to 10% off a yearly Pro and a yearly or biyearly Pro+ subscription. This could provide valuable context to the recent insider transactions and offer a broader understanding of the company’s trajectory.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.